prostate cancerultrasonic diagnosticsdoppler ultrasonic methodsonoflexographymultiparametri magnetic resonance imagingspectroscopydiffusiondynamic examinationcontrast enhancedрак предстательной железыультразвуковая диагностикадопплерографиясоноэластографиямультипараметрическая магнитно-резонансная томографияспектроскопиядиффузиядинамическое исследованиеконтрастное усиление1.1. Переверзев А.С. Рак предстательной железы: где мы сейчас находимся? Новости мед и фармац 2009;3–4:15–8.Переверзев А.С. Рак предстательной железы: где мы сейчас находимся? Новости мед и фармац 2009;3–4:15–8.2.2. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2004 г. Вестн РОНЦ им. Н.Н. Блохина РАМН 2006;17(3): 82–93.Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2004 г. Вестн РОНЦ им. Н.Н. Блохина РАМН 2006;17(3): 82–93.3.3. White S., Hricak H., Forstner R. et al. Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images. Radiology 1995;195:385–90.White S., Hricak H., Forstner R. et al. Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images. Radiology 1995;195:385–90.4.4. Hara T., Kosaka N., Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998;39:990–5.Hara T., Kosaka N., Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998;39:990–5.5.5. DeGrado T.R., Coleman R.E., Wang S. et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001;61:110–7.DeGrado T.R., Coleman R.E., Wang S. et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001;61:110–7.6.6. Hara T., Kosaka N., Kishi H. Development of 18F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 2002;43:187–99.Hara T., Kosaka N., Kishi H. Development of 18F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 2002;43:187–99.7.7. Yu K.K., Scheidler J., Hricak H. et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 1999;213:481–8.Yu K.K., Scheidler J., Hricak H. et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 1999;213:481–8.8.8. Scheidler J., Hricak H., Vigneron D.B. et al. Prostate cancer: localization with threedimensional proton MR spectroscopic imaging—clinicopathologic study. Radiology 1999;213:473–80.Scheidler J., Hricak H., Vigneron D.B. et al. Prostate cancer: localization with threedimensional proton MR spectroscopic imaging—clinicopathologic study. Radiology 1999;213:473–80.9.9. Rodriguez-González A., Molina A.R., Benitez-Rajal J., Lacal J.C. Phospholipase D and choline kinase: their role in cancer development and their potential as drug targets. Prog Cell Cycle Res 2003;5:191–201.Rodriguez-González A., Molina A.R., Benitez-Rajal J., Lacal J.C. Phospholipase D and choline kinase: their role in cancer development and their potential as drug targets. Prog Cell Cycle Res 2003;5:191–201.10.10. Rodriguez-González A., Molina A.R., Fernández F. et al. Inhibition of choline kinase as a specific cytotoxic strategy in oncogenetransformed cells. Oncogene 2003;22:8803–12.Rodriguez-González A., Molina A.R., Fernández F. et al. Inhibition of choline kinase as a specific cytotoxic strategy in oncogenetransformed cells. Oncogene 2003;22:8803–12.11.11. Ramirez de Molina A., Rodriguez-Gonzalez A., Gutierrez R. et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers.Biochem Biophys Res Commun 2002;296:580–3.Ramirez de Molina A., Rodriguez-Gonzalez A., Gutierrez R. et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers.Biochem Biophys Res Commun 2002;296:580–3.12.12. Roivainen A., Forsback S., Gronroos T. et al. Blood metabolism of [methyl-11C] choline: implications for in vivo imaging with positron emission tomography. Eur J Nucl Med 2000;27:25–32.Roivainen A., Forsback S., Gronroos T. et al. Blood metabolism of [methyl-11C] choline: implications for in vivo imaging with positron emission tomography. Eur J Nucl Med 2000;27:25–32.13.13. Kotzerke J., Gschwend J.E., Neumaier B. PET for prostate cancer imaging: still a quandary or the ultimate solution? J Nucl Med 2002;43:200–2.Kotzerke J., Gschwend J.E., Neumaier B. PET for prostate cancer imaging: still a quandary or the ultimate solution? J Nucl Med 2002;43:200–2.14.14. Kotzerke J., Volkmer B.G., Neumaier B. et al. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2002;29:1380–94.Kotzerke J., Volkmer B.G., Neumaier B. et al. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2002;29:1380–94.15.15. Kotzerke J., Volkmer B.G., Glatting G. et al. Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 2003;42:25–30.Kotzerke J., Volkmer B.G., Glatting G. et al. Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 2003;42:25–30.16.16. Ophir J., Cespedes I., Ponnekanti H. et al. Elastography: a quantitative method for imaging the elasticity of biological tissues. Ultrason Imaging 1991;13:111–34.Ophir J., Cespedes I., Ponnekanti H. et al. Elastography: a quantitative method for imaging the elasticity of biological tissues. Ultrason Imaging 1991;13:111–34.17.17. Pallwein L., Mitterberger M., Pinggera G., et al. Sonoelastography of the prostate: comparison with systematic biopsy findings in 492 patients. Eur J Radiol 2008;65(2):304–10.Pallwein L., Mitterberger M., Pinggera G., et al. Sonoelastography of the prostate: comparison with systematic biopsy findings in 492 patients. Eur J Radiol 2008;65(2):304–10.18.18. Aigner F., Pallwein L., Schocke M. et al. Comparison of real-time sonoelastography with T2-weighted endorectal magnetic resonance imaging for prostate cancer detection. J Ultrasound Med 2011;30(5):643–9.Aigner F., Pallwein L., Schocke M. et al. Comparison of real-time sonoelastography with T2-weighted endorectal magnetic resonance imaging for prostate cancer detection. J Ultrasound Med 2011;30(5):643–9.19.19. Brock M., von Bodman C., Palisaar R.J. et al. The impact of real-time elastography guiding a systematic prostate biopsy to improve cancer detection rate: a prospective study of 353 patients. J Urol 2012;187(6):2039–43.Brock M., von Bodman C., Palisaar R.J. et al. The impact of real-time elastography guiding a systematic prostate biopsy to improve cancer detection rate: a prospective study of 353 patients. J Urol 2012;187(6):2039–43.20.20. Brock M., Eggert T., Löppenberg B. et al. Value of real-time elastography to guide the systematic prostate biopsy in men with normal digital rectal exam. Aktuelle Urol 2013;44(1):40–4.Brock M., Eggert T., Löppenberg B. et al. Value of real-time elastography to guide the systematic prostate biopsy in men with normal digital rectal exam. Aktuelle Urol 2013;44(1):40–4.21.21. Eggert T., Khaled W., Wenske S. et al. Impact of elastography in clinical diagnosis of prostate cancer. A comparison of cancer detection between B-mode sonography and elastography-guided 10-core biopsies.Urologe A 2008;47(9):1212–7.Eggert T., Khaled W., Wenske S. et al. Impact of elastography in clinical diagnosis of prostate cancer. A comparison of cancer detection between B-mode sonography and elastography-guided 10-core biopsies.Urologe A 2008;47(9):1212–7.22.22. Mukhomor A.I., Bubnov R.V. Using modern radiological methods for prostate cancer diagnostics. Lik Sprava 2010; (5–6):118–23.Mukhomor A.I., Bubnov R.V. Using modern radiological methods for prostate cancer diagnostics. Lik Sprava 2010; (5–6):118–23.23.23. Abdullaiev R.Ya., Mukhomor O.I., Bubnov R.V. New promising tendencies for updating prostate cancer management algorithm. 3D vector modeling guided approach for biopsy and treatment planning. Українська асоціація фахівців з ультразвукової діагностики. IV Конгрес: Матеріали і тези, 14–16 травня 2012 р. Киев: ВБО «Український допплерівський клуб», 2012. С. 51–2.Abdullaiev R.Ya., Mukhomor O.I., Bubnov R.V. New promising tendencies for updating prostate cancer management algorithm. 3D vector modeling guided approach for biopsy and treatment planning. Українська асоціація фахівців з ультразвукової діагностики. IV Конгрес: Матеріали і тези, 14–16 травня 2012 р. Киев: ВБО «Український допплерівський клуб», 2012. С. 51–2.24.24. Rifkin M.D., Sudakoff G.S., Alexander A.A. Prostate: techniques, results, and potential applications of color Doppler US scanning. Radiology 1993;186:509–13.Rifkin M.D., Sudakoff G.S., Alexander A.A. Prostate: techniques, results, and potential applications of color Doppler US scanning. Radiology 1993;186:509–13.25.25. Berger A.P., Horninger W., Kektic J. et al. Vascular resistance in the prostate evaluated by colour Doppler ultrasonography: is benign prostatic hyperplasia a vascular disease? BJU Int 2006;98:587–90.Berger A.P., Horninger W., Kektic J. et al. Vascular resistance in the prostate evaluated by colour Doppler ultrasonography: is benign prostatic hyperplasia a vascular disease? BJU Int 2006;98:587–90.26.26. Зубарев А.В., Алферов С.М., Панфилова Е.А. Соноэластография в диагностике рака простаты. Кремлевская медицина. Клин вестн 2008;2:28–31.Зубарев А.В., Алферов С.М., Панфилова Е.А. Соноэластография в диагностике рака простаты. Кремлевская медицина. Клин вестн 2008;2:28–31.27.27. Goossen T.E., de la Rosette J.J., Hulsbergen-van de Kaa C.A. et al. The value of dynamic contrast enhaneced ultrasound imaging in the localization of prostate cancer. Eur Urol 2003;43:124–31.Goossen T.E., de la Rosette J.J., Hulsbergen-van de Kaa C.A. et al. The value of dynamic contrast enhaneced ultrasound imaging in the localization of prostate cancer. Eur Urol 2003;43:124–31.28.28. Wang L., Hricak H., Kattan M.W. Prediction of organ confined prostate cancer: incremental value of MRI and MRI sprectroscopic imaging to staging nomograms. Radiology 2006;238(2):597–603.Wang L., Hricak H., Kattan M.W. Prediction of organ confined prostate cancer: incremental value of MRI and MRI sprectroscopic imaging to staging nomograms. Radiology 2006;238(2):597–603.29.29. Wolf J.S.Jr, Cher M., Dall’era M. et al. The use and accuracy of crosssectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol 1995;153(3Pt2):993–9.Wolf J.S.Jr, Cher M., Dall’era M. et al. The use and accuracy of crosssectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol 1995;153(3Pt2):993–9.30.30. Salminen E., Hogg A., Binns D. et al. Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice. Acta Oncol 2002;41(5):425–9.Salminen E., Hogg A., Binns D. et al. Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice. Acta Oncol 2002;41(5):425–9.31.31. Husarik D.B., Miralbell R., Dubs M. et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35(2):253–63.Husarik D.B., Miralbell R., Dubs M. et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35(2):253–63.32.32. Schiavina R., Scattoni V., Castellucci P. et al. 11C-choline positron emission tomography/computerized tomography for preoperative lymphnode staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 2008;54(2):392–401.Schiavina R., Scattoni V., Castellucci P. et al. 11C-choline positron emission tomography/computerized tomography for preoperative lymphnode staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 2008;54(2):392–401.33.33. Krause B.J., Souvatzoglou M., Treiber U. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates. Urol Oncol 2011 Mar.Krause B.J., Souvatzoglou M., Treiber U. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates. Urol Oncol 2011 Mar.34.34. de Jong I.J., Pruim J., Elsinga P.H. et al. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med. 2003;44:331–5.de Jong I.J., Pruim J., Elsinga P.H. et al. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med. 2003;44:331–5.35.35. Liney G.P., Turnbull L.W., Knowles A. J. In vivo magnetic resonance spectroscopy and dynamic contrast enhanced imaging of the prostate gland. NMR Biomed 1999, 12(1):39–44.Liney G.P., Turnbull L.W., Knowles A. J. In vivo magnetic resonance spectroscopy and dynamic contrast enhanced imaging of the prostate gland. NMR Biomed 1999, 12(1):39–44.36.36. Rouviere O., Raudrant A., Ecochard R. et al. Characterization of time-enhancement curves of benign and malignant prostate tissue at dynamic MR imaging. Eur Radiol 2003;13(5):931–42.Rouviere O., Raudrant A., Ecochard R. et al. Characterization of time-enhancement curves of benign and malignant prostate tissue at dynamic MR imaging. Eur Radiol 2003;13(5):931–42.37.37. Oyen R.H. Dynamic contrast-enhanced MRI of the prostate: is this the way to proceed for characterization of prostatic carcinoma? Eur Radiol 2003;13(5):921–4.Oyen R.H. Dynamic contrast-enhanced MRI of the prostate: is this the way to proceed for characterization of prostatic carcinoma? Eur Radiol 2003;13(5):921–4.38.38. Cheikh A.B., Girouin N., Colombel M. et al. Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy. Eur Radiol 2009;19(3):770–8.Cheikh A.B., Girouin N., Colombel M. et al. Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy. Eur Radiol 2009;19(3):770–8.39.39. Futterer J.J., Heijmink S.W., Scheenen T.W. et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006;241(2):449–58.Futterer J.J., Heijmink S.W., Scheenen T.W. et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006;241(2):449–58.40.40. Jackson A.S., Reinsberg S.A., Sohaib S.A. et al. Dynamic contrast-enhanced MRI for prostate cancer localization. Br J Radiol 2009;82(974):148–56.Jackson A.S., Reinsberg S.A., Sohaib S.A. et al. Dynamic contrast-enhanced MRI for prostate cancer localization. Br J Radiol 2009;82(974):148–56.41.41. Kirkham A.P., Emberton M., Allen C. How good is MRI at detecting and characterizing cancer within the prostate? Eur Urol 2006;50(6):1163–74.Kirkham A.P., Emberton M., Allen C. How good is MRI at detecting and characterizing cancer within the prostate? Eur Urol 2006;50(6):1163–74.42.42. Rouviere O., Hartman R.P., Lyonnet D. Prostate MR imaging at high-field strength: evolution or revolution? Eur Radiol 2006;16(2):276–84.Rouviere O., Hartman R.P., Lyonnet D. Prostate MR imaging at high-field strength: evolution or revolution? Eur Radiol 2006;16(2):276–84.43.43. Villers A., Puech P., Mouton D. et al. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 2006;176(6 Pt 1):2432–7.Villers A., Puech P., Mouton D. et al. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 2006;176(6 Pt 1):2432–7.44.44. Tanimoto A., Nakashima J., Kohno H. et al. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 2007;25(1):146–52.Tanimoto A., Nakashima J., Kohno H. et al. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 2007;25(1):146–52.